Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
Holding HUMA?
Track your performance easily
HUMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.48 - $9.97
Previous Close$4.64
Volume75.49M
Average Volume (3M)4.25M
Market Cap
$445.19M
Enterprise Value$504.01M
Total Cash (Recent Filing)$20.57M
Total Debt (Recent Filing)$79.38M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 21, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding125,859,496
10 Day Avg. Volume2,597,676
30 Day Avg. Volume4,245,591
Standard Deviation0.30
R-Squared0.05
Alpha-0.00375
Financial Highlights & Ratios
Price to Book (P/B)-9.10
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$11.20Price Target Upside141.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Humacyte News
PremiumCompany Announcements
Humacyte Receives FDA Approval for SYMVESS Launch
Bulls Say, Bears Say
Bulls Say
Clinical ValidationThe ATEV clinical value proposition in vascular trauma was highlighted in a recent JAMA publication analyzing the V005 and V017 clinical trials.
Market StrategyHUMA has recruited and trained a highly experienced sales force to support the SYMVESS launch, effectively addressing the US market opportunity.
Regulatory ApprovalHUMA received FDA approval for SYMVESS in the treatment of patients with vascular trauma injury, unlocking access to the attractive US vascular trauma market.
Bears Say
Adverse EventsHigher adverse event rates observed for ATEV in the analysis, with thrombosis being the largest area of difference in adverse events.
Clinical TrialsRisks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and failure of products to show sufficient competitive differentiation.
Infection And Thrombosis RisksThere is a higher risk of infection and thrombosis with AVGs, and there is also a quicker functional decline compared to AVF.
---
Ownership Overview
5.93% Insiders
6.22% Mutual Funds
3.21% Other Institutional Investors
74.27% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $2.48 and its highest was $9.97 in the past 12 months.
What is Humacyte’s market cap?
Currently, no data Available
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Mar 21, 2025 which is in 89 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Nov 08, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.249 by -$0.081.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -$0.25.
How many shares outstanding does Humacyte have?
Humacyte has 128,668,490 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.249. Following the earnings report the stock price went up 9.886%.
Which hedge fund is a major shareholder of Humacyte?
Among the largest hedge funds holding Humacyte’s share is Woodline Partners LP. It holds Humacyte’s shares valued at 5M.
---
Humacyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.20 (141.38% Upside)
$11.20 (141.38% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 809.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
69.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.18%
Trailing 12-Months
Company Description
Humacyte
Alpha Healthcare Acquisition Corp is a blank check company.
---
HUMA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant clinical advancements and strategic progress, particularly in the areas of regulatory achievements and clinical trial results. However, the delay in FDA review and increased financial losses pose notable challenges.Read More>---
HUMA Stock 12 Month Forecast
Average Price Target
$11.20
▲(141.38% Upside)
Technical Analysis
Best Analysts Covering HUMA
1 Year
1 Year Success Rate
9/21 ratings generated profit
1 Year Average Return
-4.86%
reiterated a buy rating 2 days ago
Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -4.86% per trade.
---